The Europe Large Molecule Drug Substance CDMO Market should witness market growth of 8.4% CAGR during the forecast period (2022-2028).
In the pharmaceutical sector, biologics are currently emerging as a therapeutic molecules’ next-generation. The large size and complexity of biologics forbid their production through existing methods. Instead, biologics are mostly recombinantly synthesized by engineered cells. Biologics pharmaceuticals or biopharmaceuticals bind to cells externally to induce the needed cellular response.
Additionally, since biologics can perform target-specific cellular binding, their interference with healthy cells becomes negligible, eventually increasing the use of these drugs. CDMOs are preferred for large molecules as these kinds of molecules are produced through complex steps, often over 1000. Biologics work by moving drugs to targeted locations in the body without releasing them before the specified location.
Large molecule drugs are mostly given as infusions or injections as they are ineffective when consumed orally. Vaccines, blood components, blood, tissue, gene therapy, and some proteins primarily constitute large molecule drug substances. In the past few years, research regarding the development of large molecule drugs has been rising rapidly as they have the potential to offer medications for medical conditions that have no other treatment alternative.
The rising disease burden prevalence has propelled biopharmaceutical firms to develop efficient drugs to tackle the increasing number of heart disorders. The region's governments are also specifying laws that would aid in the manufacture and approval of many drugs. For example, an expansive list of available guidelines and opportunities for the involvement of CDMOs during the development stage of a medicinal product has been formed by European Medicines Agency (EMA).
The Germany market dominated the Europe Large Molecule Drug Substance CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1, 216.8 million by 2028. The UK market is anticipated to grow at a CAGR of 7.5% during (2022-2028). Additionally, The France market would exhibit a CAGR of 9.2% during (2022-2028).
Based on Application, the market is segmented into Mammalian, Microbial and Others. Based on Service, the market is segmented into Contract Manufacturing and Contract Development. Based on Contract Manufacturing Type, the market is segmented into Commercial and Clinical. Based on Contract Development Type, the market is segmented into Cell Line Development and Process Development. Based on End-user, the market is segmented into Biotech Companies, CRO and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eurofins Scientific SE, WuXi Biologics (Cayman), Inc, Catalent, Inc., Boehringer Ingelheim International GmbH, FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation), Samsung Biologics Co., Ltd. (Samsung Group), Rentschler Biopharma SE, AGC Biologics, Inc. (AGC, Inc.), Recipharm AB (EQT AB), and Siegfried Holding AG.
In the pharmaceutical sector, biologics are currently emerging as a therapeutic molecules’ next-generation. The large size and complexity of biologics forbid their production through existing methods. Instead, biologics are mostly recombinantly synthesized by engineered cells. Biologics pharmaceuticals or biopharmaceuticals bind to cells externally to induce the needed cellular response.
Additionally, since biologics can perform target-specific cellular binding, their interference with healthy cells becomes negligible, eventually increasing the use of these drugs. CDMOs are preferred for large molecules as these kinds of molecules are produced through complex steps, often over 1000. Biologics work by moving drugs to targeted locations in the body without releasing them before the specified location.
Large molecule drugs are mostly given as infusions or injections as they are ineffective when consumed orally. Vaccines, blood components, blood, tissue, gene therapy, and some proteins primarily constitute large molecule drug substances. In the past few years, research regarding the development of large molecule drugs has been rising rapidly as they have the potential to offer medications for medical conditions that have no other treatment alternative.
The rising disease burden prevalence has propelled biopharmaceutical firms to develop efficient drugs to tackle the increasing number of heart disorders. The region's governments are also specifying laws that would aid in the manufacture and approval of many drugs. For example, an expansive list of available guidelines and opportunities for the involvement of CDMOs during the development stage of a medicinal product has been formed by European Medicines Agency (EMA).
The Germany market dominated the Europe Large Molecule Drug Substance CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1, 216.8 million by 2028. The UK market is anticipated to grow at a CAGR of 7.5% during (2022-2028). Additionally, The France market would exhibit a CAGR of 9.2% during (2022-2028).
Based on Application, the market is segmented into Mammalian, Microbial and Others. Based on Service, the market is segmented into Contract Manufacturing and Contract Development. Based on Contract Manufacturing Type, the market is segmented into Commercial and Clinical. Based on Contract Development Type, the market is segmented into Cell Line Development and Process Development. Based on End-user, the market is segmented into Biotech Companies, CRO and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eurofins Scientific SE, WuXi Biologics (Cayman), Inc, Catalent, Inc., Boehringer Ingelheim International GmbH, FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation), Samsung Biologics Co., Ltd. (Samsung Group), Rentschler Biopharma SE, AGC Biologics, Inc. (AGC, Inc.), Recipharm AB (EQT AB), and Siegfried Holding AG.
Scope of the Study
By Application
- Mammalian
- Microbial
- Others
By Service
- Contract Manufacturing
- Commercial
- Clinical
- Contract Development
- Cell Line Development
- Process Development
By End-user
- Biotech Companies
- CRO
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Eurofins Scientific SE
- WuXi Biologics (Cayman), Inc
- Catalent, Inc.
- Boehringer Ingelheim International GmbH
- FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation)
- Samsung Biologics Co., Ltd. (Samsung Group)
- Rentschler Biopharma SE
- AGC Biologics, Inc. (AGC, Inc.)
- Recipharm AB (EQT AB)
- Siegfried Holding AG
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Large Molecule Drug Substance CDMO Market, by Application
1.4.2 Europe Large Molecule Drug Substance CDMO Market, by Service
1.4.3 Europe Large Molecule Drug Substance CDMO Market, by End-user
1.4.4 Europe Large Molecule Drug Substance CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2019, Apr- 2022, Oct) Leading Players
3.3.3 Key Strategic Move: (Acquisitions and Mergers : 2018, Oct - 2022, Aug) Leading Players
Chapter 4. Europe Large Molecule Drug Substance CDMO Market by Application
4.1 Europe Mammalian Market by Country
4.2 Europe Microbial Market by Country
4.3 Europe Other Application Market by Country
Chapter 5. Europe Large Molecule Drug Substance CDMO Market by Service
5.1 Europe Contract Manufacturing Market by Country
5.2 Europe Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
5.2.1 Europe Commercial Market by Country
5.2.2 Europe Clinical Market by Country
5.3 Europe Contract Development Market by Country
5.4 Europe Large Molecule Drug Substance CDMO Market by Contract Development Type
5.4.1 Europe Cell Line Development Market by Country
5.4.2 Europe Process Development Market by Country
Chapter 6. Europe Large Molecule Drug Substance CDMO Market by End-user
6.1 Europe Biotech Companies Market by Country
6.2 Europe CRO Market by Country
6.3 Europe Others Market by Country
Chapter 7. Europe Large Molecule Drug Substance CDMO Market by Country
7.1 Germany Large Molecule Drug Substance CDMO Market
7.1.1 Germany Large Molecule Drug Substance CDMO Market by Application
7.1.2 Germany Large Molecule Drug Substance CDMO Market by Service
7.1.2.1 Germany Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.1.2.2 Germany Large Molecule Drug Substance CDMO Market by Contract Development Type
7.1.3 Germany Large Molecule Drug Substance CDMO Market by End-user
7.2 UK Large Molecule Drug Substance CDMO Market
7.2.1 UK Large Molecule Drug Substance CDMO Market by Application
7.2.2 UK Large Molecule Drug Substance CDMO Market by Service
7.2.2.1 UK Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.2.2.2 UK Large Molecule Drug Substance CDMO Market by Contract Development Type
7.2.3 UK Large Molecule Drug Substance CDMO Market by End-user
7.3 France Large Molecule Drug Substance CDMO Market
7.3.1 France Large Molecule Drug Substance CDMO Market by Application
7.3.2 France Large Molecule Drug Substance CDMO Market by Service
7.3.2.1 France Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.3.2.2 France Large Molecule Drug Substance CDMO Market by Contract Development Type
7.3.3 France Large Molecule Drug Substance CDMO Market by End-user
7.4 Russia Large Molecule Drug Substance CDMO Market
7.4.1 Russia Large Molecule Drug Substance CDMO Market by Application
7.4.2 Russia Large Molecule Drug Substance CDMO Market by Service
7.4.2.1 Russia Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.4.2.2 Russia Large Molecule Drug Substance CDMO Market by Contract Development Type
7.4.3 Russia Large Molecule Drug Substance CDMO Market by End-user
7.5 Spain Large Molecule Drug Substance CDMO Market
7.5.1 Spain Large Molecule Drug Substance CDMO Market by Application
7.5.2 Spain Large Molecule Drug Substance CDMO Market by Service
7.5.2.1 Spain Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.5.2.2 Spain Large Molecule Drug Substance CDMO Market by Contract Development Type
7.5.3 Spain Large Molecule Drug Substance CDMO Market by End-user
7.6 Italy Large Molecule Drug Substance CDMO Market
7.6.1 Italy Large Molecule Drug Substance CDMO Market by Application
7.6.2 Italy Large Molecule Drug Substance CDMO Market by Service
7.6.2.1 Italy Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.6.2.2 Italy Large Molecule Drug Substance CDMO Market by Contract Development Type
7.6.3 Italy Large Molecule Drug Substance CDMO Market by End-user
7.7 Rest of Europe Large Molecule Drug Substance CDMO Market
7.7.1 Rest of Europe Large Molecule Drug Substance CDMO Market by Application
7.7.2 Rest of Europe Large Molecule Drug Substance CDMO Market by Service
7.7.2.1 Rest of Europe Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.7.2.2 Rest of Europe Large Molecule Drug Substance CDMO Market by Contract Development Type
7.7.3 Rest of Europe Large Molecule Drug Substance CDMO Market by End-user
Chapter 8. Company Profiles
8.1 Teledyne FLIR LLC (Teledyne Technologies Incorporated)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations and Agreements:
8.1.4.2 Product Launches and Product Expansions:
8.1.5 SWOT Analysis
8.2 Hikvision Digital Technology Co., Ltd., (China Electronics Technology Group Corporation)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.2.4.2 Product Launches and Product Expansions:
8.3 Axis Communications AB (Canon, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Product Launches and Product Expansions:
8.4 Bosch Security Systems GmbH (Robert Bosch GmbH)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Product Launches and Product Expansions:
8.5 Avigilon Corporation (Motorola Solutions)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional & Segmental Analysis
8.5.4 Research & Development Expenses
8.6 Hanwha Techwin Co., Ltd. (Hanwha Group)
8.6.1 Company Overview
8.6.2 Recent strategies and developments:
8.6.2.1 Partnerships, Collaborations, and Agreements:
8.6.2.2 Product Launches and Product Expansions:
8.7 Zhejiang Dahua Technology Co., Ltd.
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Product Launches and Product Expansions:
8.8 Zhejiang Uniview Technologies Co., Ltd. (Hangzhou Jiaozhi Technology Co., Ltd.)
8.8.1 Company Overview
8.8.2 Recent strategies and developments:
8.8.2.1 Partnerships, Collaborations, and Agreements:
Companies Mentioned
- Eurofins Scientific SE
- WuXi Biologics (Cayman), Inc
- Catalent, Inc.
- Boehringer Ingelheim International GmbH
- FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation)
- Samsung Biologics Co., Ltd. (Samsung Group)
- Rentschler Biopharma SE
- AGC Biologics, Inc. (AGC, Inc.)
- Recipharm AB (EQT AB)
- Siegfried Holding AG
Methodology
LOADING...
